Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuno-guided versus universal valganciclovir prophylaxis for cytomegalovirus in renal transplant recipients
2022-002556-39Phase 3Active
- Sponsor
- Rouen University Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of valganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by Rouen University Hospital. Started Nov 2022; status: active.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2022-002556-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002556-39.